Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Journal of the American Chemical Society
|
October 27, 2018
Binding Kinetics Survey of the Drugged Kinome
Victoria Georgi, Felix Schiele, Benedict-Tilman Berger, et al.
Journal of Medicinal Chemistry
|
July 15, 2021
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, et al.
Journal of Medicinal Chemistry
|
September 27, 2024
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer
Jeffrey Mowat, Rafael Carretero, Gabriele Leder, et al.
Journal of Medicinal Chemistry
|
December 21, 2019
Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
Julien Lefranc, Volker Klaus Schulze, Roman Christian Hillig, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
January 25, 2021
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
Clara Lemos, Volker K Schulze, Simon J Baumgart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>
Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 27, 2019
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C Hillig, Brice Sautier, Jens Schroeder, et al.
Journal of Medicinal Chemistry
|
August 24, 2021
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
Markus Berger, Lars Wortmann, Philipp Buchgraber, et al.
Journal of Medicinal Chemistry
|
June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
Ulrich Lücking, Lars Wortmann, Antje M Wengner, et al.
Chemmedchem
|
September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
Ulrich Lücking, Arne Scholz, Philip Lienau, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Journal of the American Chemical Society
|
October 27, 2018
Binding Kinetics Survey of the Drugged Kinome
Victoria Georgi, Felix Schiele, Benedict-Tilman Berger, et al.
Journal of Medicinal Chemistry
|
July 15, 2021
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, et al.
Journal of Medicinal Chemistry
|
September 27, 2024
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer
Jeffrey Mowat, Rafael Carretero, Gabriele Leder, et al.
Journal of Medicinal Chemistry
|
December 21, 2019
Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
Julien Lefranc, Volker Klaus Schulze, Roman Christian Hillig, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
January 25, 2021
The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models
Clara Lemos, Volker K Schulze, Simon J Baumgart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2018
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>
Gerhard Siemeister, Anne Mengel, Amaury E Fernández-Montalván, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
January 27, 2019
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction
Roman C Hillig, Brice Sautier, Jens Schroeder, et al.
Journal of Medicinal Chemistry
|
August 24, 2021
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies
Markus Berger, Lars Wortmann, Philipp Buchgraber, et al.
Journal of Medicinal Chemistry
|
June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
Ulrich Lücking, Lars Wortmann, Antje M Wengner, et al.
Chemmedchem
|
September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer
Ulrich Lücking, Arne Scholz, Philip Lienau, et al.
Page
of 4